HLA-A and cancer: To evaluate the therapeutic potential of Neurofibromin 1 (<i>NF1</i>)-derived SAAVs - given that <i>NF1</i> is frequently mutated in malignant brain tumors - we prioritized the 40 <i>NF1</i> SAAVs determined to be HLA-A*02:01 binders using computational prediction coupled with experimental validation.